Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.

Coupled analysis of actionable germline PGx variants (DPYD, UGT1A1, CYP2C9, CYP2C19) and therapeutically actionable somatic mutations in TCGA

Analysis of matched germline and somatic WES data from 10,302 TCGA cancer patients (33 tumor types) reveals that 100% harbor at least one actionable germline pharmacogenetic variant (median: 3). Seventy-three percent carry variants relevant to chemotherapy toxicity or supportive care (DPYD, UGT1A1, CYP2C9, CYP2C19). Only 42% have an FDA-matched somatic mutation for targeted therapy. Strikingly, 51% of patients have more actionable germline variants than somatic mutations, underscoring the underappreciated primacy of germline pharmacogenomics in oncology.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

This work provides the most quantitative argument yet for systematic germline PGx genotyping in all cancer patients: actionable germline variants are more prevalent than somatic targets for approved targeted therapies. This reality — largely overlooked in oncology precision medicine programs — should reshape sequencing practices in oncology.

Clinical impact : 3/3 · Evidence strength : 2/3 · Novelty : 2/2 · Sample size : 1/1 · Journal quality : 1/1 → Total : 9/10